An Evaluation of Talimogene Laherparepvec for the Treatment of Melanoma.

An Evaluation of Talimogene Laherparepvec for the Treatment of Melanoma.

Publication date: Nov 05, 2019

Introduction: Intralesional therapies have emerged as effective immune therapies for locally advanced and metastatic melanoma. Talimogene laherparepvec (T-VEC), an oncolytic virus derived from the herpes simplex 1 (HSV-1) virus, is the first and only FDA approved intralesional therapy for recurrent, unresectable cutaneous, subcutaneous or nodal metastases from melanoma.Areas covered: We discuss results from clinical trials of T-VEC including data on safety, biodistribution, and viral shedding, which established the current treatment protocol and basis for FDA approval. Data are presented from early implementation of T-VEC in clinical practice. We explore use of T-VEC in the neoadjuvant setting and in combination with anti CTLA-4 and PD-1 therapies, including available evidence to support a mechanism for the observed synergistic effect.Expert opinion: Intralesional T-VEC is effective for unresectable stage III and IVa melanoma, with early clinical results comparing favorably to response rates from clinical trials. Clinical applications will likely increase as more data become available on its use in the neoadjuvant setting and in combination with other systemic immune therapies. We expect the fields of intralesional therapy and viral oncotherapy to expand as we better understand how to manipulate the tumor microenvironment and host immune response to cancer.

Broman, K. and Zager, J. An Evaluation of Talimogene Laherparepvec for the Treatment of Melanoma. 24698. 2019 Expert Opin Biol Ther.

Concepts Keywords
Cancer Herpes
Clinical Trials Treatment protocol
FDA Medicine
Herpes Simplex Clinical medicine
HSV Virotherapy
Melanoma Experimental cancer treatments
Metastases Biotechnology
Neoadjuvant Health
Oncolytic Virus Amgen
Protocol Talimogene laherparepvec
Subcutaneous Melanoma
Synergistic Oncolytic virus
Viral Immunotherapy
Viral Shedding
Virus

Semantics

Type Source Name
drug DRUGBANK Talimogene laherparepvec
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH herpes simplex
disease DOID herpes simplex
gene UNIPROT NODAL
disease MESH metastases
disease MESH viral shedding
gene UNIPROT CTLA4
gene UNIPROT RPL17
drug DRUGBANK Tropicamide
disease MESH tumor
disease DOID cancer

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *